ArticleEpilepsy & behavior : E&B2026
Cenobamate's effect on mood and seizure frequency.
Article in Epilepsy & behavior : E&B, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
objectiveReal-world experience with efficacy and tolerability of newly approved antiseizure medications (ASM) often diverges from findings in their controlled clinical trials. Cenobamate (CNB), demonstrated a high responder rate and seizure freedom in placebo-controlled trials. Since 40% of patients with epilepsy (PWE) experience comorbid depression, understanding the potential mood-related effects of CNB is critical. This retrospective study evaluates the impact of CNB on mood, tolerability, and seizure control when used as adjunctive therapy at our institution.
methodsA single-center retrospective chart review was conducted of adult patients with refractory focal epilepsy who initiated CNB add-on therapy (May 2020-July 2023). We assessed changes in depressive symptoms and seizure frequency. Eligibility required ≥3 months on CNB, seizure frequency available at baseline and last follow-up (events/30 days), and paired Patient Health Questionnaire-9 (PHQ-9) scores. Seizure outcomes were analyzed as paired change (ΔSeizures), as log
results73 adult PWE met study criteria. Median seizure frequency fell from 5 at baseline to 1.5 per 30 days at the last follow-up (p < 0.001), with a 50% median reduction (95% CI: 70%-19%) in seizure frequency within a median of 488 days of follow-up. At the last follow-up, 29% of patients were seizure-free overall. PHQ-9 scores did not worsen (median ΔPHQ-9 = 0 (HL = 0; 95% CI -2 to 0; 0.34), and in multiple linear regressions of ΔPHQ-9, no prespecified covariates were associated with mood outcomes.
conclusionOur findings suggest that CNB is a safe and effective adjunctive ASM that improves seizure control in PWE and that does not significantly change PHQ-9 scores. While better seizure control may mask the drug's potential effects on mood-as reduced seizure burden itself could influence depressive symptoms-its impact on individual mood was variable. These results highlight the need for further research. SIMPLE LANGUAGE SUMMARY: Patients with epilepsy often experience depression, making it important to assess whether new antiseizure medications affect mood. This study reviewed medical records of patients prescribed cenobamate (Xcopri) between May 2020 and August 2023. The results showed that cenobamate helped improve seizure control, and most patients did not experience a worsening of mood. These findings suggest that cenobamate is a safe option for epilepsy treatment, although further research is needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.